Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Indobufen→

Indobufen Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
63610-08-2
Molecular formula
C18H17NO3
Molecular weight
295.3 g/mol
Drug class
Reversible cyclooxygenase inhibitorantiplatelet agent
Mechanism of action
Reversibly inhibits platelet cyclooxygenase, reducing thromboxane A2 synthesis and platelet aggregation. Platelet function recovers as the drug is cleared, unlike the irreversible effect of aspirin.
Indications / reported uses
  • Prevention of thromboembolic events in selected patients with cardiovascular or cerebrovascular disease under local product authorisation; indication and use relative to other antiplatelets are jurisdiction-specific.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3719 · https://pubmed.ncbi.nlm.nih.gov/?term=indobufen+platelet+cyclooxygenase+clinical · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Indobufen Environmental Risk Assessment (ERA) (the Indobufen ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.